Adipiplon

Not to be confused with adipiodone.
Adipiplon
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 840486-93-3 N
ChemSpider 9373993 YesY
UNII OPL214POJ1 YesY
KEGG D08840 YesY
ChEMBL CHEMBL2103791 N
Chemical and physical data
Formula C18H18FN7
Molar mass 351.38 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Adipiplon (NG2-73) is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

Adipiplon is a subtype-selective GABAA receptor partial agonist, which binds preferentially to the α3 subtype. This is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for α2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which is able to discriminate between α2 and α3, as well as showing little affinity for the α1 or α5 subtypes - alpidem is selective for α3 over α2, but still has moderate affinity for α1, whereas adipiplon is highly α3-selective with little affinity for either α1, α2 or α5.

Adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and is currently (as of 2008) in Phase IIb trials.[1][2][3]

See also

References

  1. ↑ Pipeline Summary GABA: Adipiplon Archived April 11, 2008, at the Wayback Machine.
  2. ↑ Neurogen Announces Adipiplon Preclinical and Clinical Data
  3. ↑ Meet Adipiplon: The New Insomnia Drug Archived April 15, 2008, at the Wayback Machine.



This article is issued from Wikipedia - version of the 11/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.